posted at 21:50
Author: Business Wire
Fri, 31 Oct 2014 04:01:12 +0000
Xcovery Presents Phase 1 Results of X-396 in ALK positive NSCLC at the 2014 Multidisciplinary Symposium in Thoracic Oncology
"While still early, X-396 continues to demonstrate activity in treatment-naive ALK-positive non-small cell lung cancer patients as well as those that have progressed on crizotinib, and responses have also been seen in patients with central nervous system disease," said Leora Horn, MD, MSc, Associate Professor of Medicine and Clinical Director, Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Nashville, Tenn., and lead investigator of this Phase 1 study. "We are continuing to enroll patients in the expansion cohort phase of this trial to learn more about this patient population and inform future studies of X-396.". At the time of data cutoff, 41 patients were enrolled with tumor types including NSCLC, head and neck, small cell lung, colorectal and breast cancers. The NSCLC patient group included ALK-positive patients who were either crizotinib-naïve or received prior crizotinib, as well as ceritinib in two patients. Among the 17 ALK positive patients evaluable for response, 10 patients had a partial response and two had stable disease. For the five patients with progressive disease, two were at lower doses with acquired resistance to crizotinib, one had failed prior crizotinib and chemotherapy, and one had failed prior crizotinib and ceritinib. The patient with prior crizotinib and ceritinib had a complete response to X-396 in a retroperitoneal lymph node but progression of bone/CNS metastases. Founded by Sheridan G. Snyder and Chris Liang, Ph.D., Xcovery's vision is to successfully develop innovative oncology therapies to optimize patient outcomes.

Posts Archive